CNR1 and depressive symptom measurement: As mentioned above, Pep19 is an exciting novel CB1R-targeting molecule to treat overweight, obesity, and metabolic disorders because it does not induce anxiety or depression-like symptoms, nor can it induce cannabinoid tetrad behavior or activate cerebral areas related to CB1R activation [67].